LLY

1,008.06

+2%↑

JNJ

242.47

+0.89%↑

ABBV

227.83

-0.92%↓

NVS

162.82

+1.92%↑

AZN

194.72

+0.18%↑

LLY

1,008.06

+2%↑

JNJ

242.47

+0.89%↑

ABBV

227.83

-0.92%↓

NVS

162.82

+1.92%↑

AZN

194.72

+0.18%↑

LLY

1,008.06

+2%↑

JNJ

242.47

+0.89%↑

ABBV

227.83

-0.92%↓

NVS

162.82

+1.92%↑

AZN

194.72

+0.18%↑

LLY

1,008.06

+2%↑

JNJ

242.47

+0.89%↑

ABBV

227.83

-0.92%↓

NVS

162.82

+1.92%↑

AZN

194.72

+0.18%↑

LLY

1,008.06

+2%↑

JNJ

242.47

+0.89%↑

ABBV

227.83

-0.92%↓

NVS

162.82

+1.92%↑

AZN

194.72

+0.18%↑

Kodu・Aktsiate loetelu・Arbutus Biopharma Corp

Arbutus Biopharma Corp

Suletud

4.73 4.19

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

4.33

Max

4.79

Põhinäitajad
By Trading Economics
Sissetulek	-10M -7.7M
Müük	-10M 529K
Kasumimarginaal	-1,463.516
Töötajad	44
EBITDA	-10M -7.7M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+54.53% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	26. märts 2026

Turustatistika
By TradingEconomics
Turukapital	18M 898M
Eelmine avamishind	0.54
Eelmine sulgemishind	4.73

Tehniline skoor

By Trading Central

Kindlus

Weak Bearish Evidence

3.255 / 3.365 Toetus ja vastupanu

Arbutus Biopharma Corp Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

9. märts 2026, 18:13 UTC

Omandamised, ülevõtmised, äriostud

Shell to Sell Jiffy Lube to Monomoy in $1.3 Billion Deal -- Update

9. märts 2026, 17:20 UTC

Uudisväärsed sündmused

U.S. Ag Industry Calls for Government Intervention on Fertilizer Prices

9. märts 2026, 17:15 UTC

Omandamised, ülevõtmised, äriostud

Shell to Sell Jiffy Lube and Premium Velocity to Monomoy for $1.3 Billion

10. märts 2026, 00:00 UTC

Uudisväärsed sündmused

Why Iranian Regime Change Would Transform Global Energy Markets -- WSJ

9. märts 2026, 23:52 UTC

Market Talk

Gold Steady; May Be Supported by Dollar's Weakness -- Market Talk

9. märts 2026, 23:50 UTC

Market Talk

Nikkei May Rise as Fears About Higher Energy Prices Ease -- Market Talk

9. märts 2026, 23:50 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

9. märts 2026, 23:46 UTC

Market Talk

Uudisväärsed sündmused

Correction to Crude Prices Market Talk on March 9

9. märts 2026, 23:42 UTC

Market Talk

Uudisväärsed sündmused

Oil Futures Fall Amid Developments That Could Help Supply -- Market Talk

9. märts 2026, 23:08 UTC

Uudisväärsed sündmused

Front-Month WTI Futures Drop 7.9% to $87.29/bbl, ICE Data Show

9. märts 2026, 23:07 UTC

Uudisväärsed sündmused

Front-Month WTI Futures Fall After Trump Says Iran War Will Be Over 'Very Soon'

9. märts 2026, 21:29 UTC

Omandamised, ülevõtmised, äriostud

Fortescue Now Fully Owns Peru's Canariaco Copper Project

9. märts 2026, 21:28 UTC

Omandamised, ülevõtmised, äriostud

Fortescue Completes Acquisition of Remaining Alta Copper Shares

9. märts 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. märts 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

9. märts 2026, 20:47 UTC

Uudisväärsed sündmused

The 24 Hours When Oil Markets Went Wild -- WSJ

9. märts 2026, 20:33 UTC

Uudisväärsed sündmused

Stock Market Today: Oil Slips, Stocks Bounce on Trump War-Progress Comments Headline -- WSJ

9. märts 2026, 20:14 UTC

Market Talk

Uudisväärsed sündmused

Oil Moves Lower As Trump Says War Could End Soon -- Market Talk

9. märts 2026, 19:33 UTC

Uudisväärsed sündmused

High Oil Prices Could Crimp Convenience Store Margins -- Barrons.com

9. märts 2026, 19:17 UTC

Market Talk

Uudisväärsed sündmused

Prospect of Added Supply From Oil Reserves Ease Inflation Fears -- Market Talk

9. märts 2026, 19:14 UTC

Market Talk

Oil Settles Off Highs As G7 Discusses Tapping Reserves -- Market Talk

9. märts 2026, 19:00 UTC

Market Talk

U.S. Natural Gas Futures Settle Lower -- Market Talk

9. märts 2026, 18:23 UTC

Market Talk

Uudisväärsed sündmused

BofA Drops Canada Rate-Cut Call on Higher Oil Prices -- Market Talk

9. märts 2026, 17:58 UTC

Omandamised, ülevõtmised, äriostud

Shell to Sell Jiffy Lube to Monomoy in $1.3B Deal -- Update

9. märts 2026, 17:57 UTC

Omandamised, ülevõtmised, äriostud

Activist Investors Target Food Companies as Growth Slows. Lamb Weston Is the Latest. -- Barrons.com

9. märts 2026, 17:41 UTC

Uudisväärsed sündmused

U.S. and Western Allies Turn to Reserves to Counteract Gulf Oil Crisis -- WSJ

9. märts 2026, 17:41 UTC

Market Talk

Uudisväärsed sündmused

Reports of Saudi Production Shut-Ins Keep Bid in Crude -- Market Talk

9. märts 2026, 17:08 UTC

Market Talk

Canada Rate Outlook Shifts From Long Pause to Late 2026 Hike -- Market Talk

9. märts 2026, 17:04 UTC

Market Talk

Uudisväärsed sündmused

Global Forex and Fixed Income Roundup: Market Talk

9. märts 2026, 17:04 UTC

Market Talk

Uudisväärsed sündmused

Treasury Yields, Dollar Off Highs as G7 Tackles Oil Shock -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Arbutus Biopharma Corp Prognoos

Hinnasiht

By TipRanks

54.53% tõus

12 kuu keskmine prognoos

Keskmine 7 USD 54.53%

Kõrge 7 USD

Madal 7 USD

Põhineb 1 Wall Streeti analüütiku instrumendi Arbutus Biopharma Corp 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

1 ratings

Osta

Hoia

Müü

Põhineb 1 analüütiku instrumendi Arbutus Biopharma Corp aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

3.255 / 3.365Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.